OXBRYTA
These highlights do not include all the information needed to use OXBRYTA safely and effectively. See full prescribing information for OXBRYTA. OXBRYTA (voxelotor) tablets, for oral use OXBRYTA (voxelotor) tablets for oral suspension Initial U.S. Approval: 2019
3c557fac-29ec-483f-b691-8a935d4decc3
HUMAN PRESCRIPTION DRUG LABEL
Dec 26, 2023
Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.
DUNS: 028636495
Products 3
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Voxelotor
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (9)
Voxelotor
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (11)
Voxelotor
Product Details
FDA regulatory identification and product classification information